Literature DB >> 21688123

Bovine lactoferrin induces interleukin-11 production in a hepatitis mouse model and human intestinal myofibroblasts.

Tetsuya Kuhara1, Koji Yamauchi, Keiji Iwatsuki.   

Abstract

PURPOSE: Orally administered bovine lactoferrin (bLF) exerts an anti-inflammatory effect on hepatitis and colitis animal models. To investigate the mechanism underlying the action of bLF, we explored the expression of inflammation-related factors in the intestine of a hepatitis mouse model after the oral administration of bLF and in several human intestinal cell lines treated with bLF.
METHODS: The effects of bLF on the expression of interleukin-11 (IL-11) and bone morphogenetic protein 2 (BMP2) in the intestinal mucosa of a hepatitis mouse model as well as in cell cultures of human intestinal epithelial cells, myofibroblasts, and monocytes were examined using the real-time reverse transcription polymerase chain reaction. Epithelial cells and myofibroblasts were also cocultured using transwells. bLF transport, and IL-11 and BMP2 induction, as well as the interactions between the two cell types, were then analyzed after bLF treatment.
RESULTS: In vivo, oral bLF administration increased the production of IL-11 and BMP2 in intestinal specimens. In vitro, bLF only stimulated the production of IL-11 in human intestinal myofibroblasts; i.e., it had no effect on BMP2 production in any cell type. In the transwell cocultures, bLF passed through the epithelium and directly stimulated IL-11 production in the myofibroblasts on the basolateral side. The IL-11 produced in the myofibroblasts subsequently acted protectively on the epithelial cells of the coculture.
CONCLUSIONS: bLF upregulated the activity of anti-inflammatory factors, such as IL-11, in the intestine of a hepatitis mouse model and human intestinal myofibroblasts.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688123     DOI: 10.1007/s00394-011-0219-y

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  33 in total

Review 1.  The physiology of lactoferrin.

Authors:  Jeremy H Brock
Journal:  Biochem Cell Biol       Date:  2002       Impact factor: 3.626

2.  Lactoferrin protects against development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccharide.

Authors:  M Yamaguchi; M Matsuura; K Kobayashi; H Sasaki; T Yajima; T Kuwata
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

3.  Interleukin-11 reduces T-cell-dependent experimental liver injury in mice.

Authors:  M Bozza; J L Bliss; R Maylor; J Erickson; L Donnelly; P Bouchard; A J Dorner; W L Trepicchio
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

Review 4.  Myofibroblasts. II. Intestinal subepithelial myofibroblasts.

Authors:  D W Powell; R C Mifflin; J D Valentich; S E Crowe; J I Saada; A B West
Journal:  Am J Physiol       Date:  1999-08

5.  Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats.

Authors:  H Kuwata; K Yamauchi; S Teraguchi; Y Ushida; Y Shimokawa; T Toida; H Hayasawa
Journal:  J Nutr       Date:  2001-08       Impact factor: 4.798

6.  A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy.

Authors:  Eric J Lawitz; Matthew J Hepburn; Thomas J Casey
Journal:  Am J Gastroenterol       Date:  2004-12       Impact factor: 10.864

7.  Interleukin-11-induced heat shock protein 25 confers intestinal epithelial-specific cytoprotection from oxidant stress.

Authors:  Mark J Ropeleski; Jun Tang; Margaret M Walsh-Reitz; Mark W Musch; Eugene B Chang
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

8.  Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial.

Authors:  Paolo Manzoni; Matteo Rinaldi; Silvia Cattani; Lorenza Pugni; Mario Giovanni Romeo; Hubert Messner; Ilaria Stolfi; Lidia Decembrino; Nicola Laforgia; Federica Vagnarelli; Luigi Memo; Linda Bordignon; Onofrio Sergio Saia; Milena Maule; Elena Gallo; Michael Mostert; Cristiana Magnani; Michele Quercia; Lina Bollani; Roberto Pedicino; Livia Renzullo; Pasqua Betta; Fabio Mosca; Fabrizio Ferrari; Rosario Magaldi; Mauro Stronati; Daniele Farina
Journal:  JAMA       Date:  2009-10-07       Impact factor: 56.272

9.  Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon.

Authors:  James C H Hardwick; Gijs R Van Den Brink; Sylvia A Bleuming; Isabel Ballester; Jan M H Van Den Brande; Josbert J Keller; G Johan A Offerhaus; Sander J H Van Deventer; Maikel P Peppelenbosch
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

10.  Dose-response trial of lactoferrin in patients with chronic hepatitis C.

Authors:  Shuichi Okada; Katsuaki Tanaka; Tosiya Sato; Hideki Ueno; Satoru Saito; Takuji Okusaka; Keiko Sato; Seiichiro Yamamoto; Tadao Kakizoe
Journal:  Jpn J Cancer Res       Date:  2002-09
View more
  2 in total

1.  Three-dimensional in vivo imaging of the murine liver: a micro-computed tomography-based anatomical study.

Authors:  Teresa Fiebig; Hanne Boll; Giovanna Figueiredo; Hans Ulrich Kerl; Stefanie Nittka; Christoph Groden; Martin Kramer; Marc A Brockmann
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

Review 2.  Lactoferrin: Balancing Ups and Downs of Inflammation Due to Microbial Infections.

Authors:  Maria Elisa Drago-Serrano; Rafael Campos-Rodríguez; Julio César Carrero; Mireya de la Garza
Journal:  Int J Mol Sci       Date:  2017-03-01       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.